- Home
- HYFM vs CVM Comparison
HYFM vs CVM Comparison
Compare HYFM & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- CVM
- Stock Information
- Founded
- HYFM 1977
- CVM 1983
- Country
- HYFM United States
- CVM United States
- Employees
- HYFM N/A
- CVM N/A
- Industry
- HYFM Industrial Machinery/Components
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYFM Industrials
- CVM Health Care
- Exchange
- HYFM Nasdaq
- CVM Nasdaq
- Market Cap
- HYFM 38.1M
- CVM 40.1M
- IPO Year
- HYFM 2020
- CVM 1987
- Fundamental
- Price
- HYFM $0.61
- CVM $0.41
- Analyst Decision
- HYFM Hold
- CVM
- Analyst Count
- HYFM 2
- CVM 0
- Target Price
- HYFM $0.70
- CVM N/A
- AVG Volume (30 Days)
- HYFM 114.8K
- CVM 1.5M
- Earning Date
- HYFM 02-27-2025
- CVM 01-13-2025
- Dividend Yield
- HYFM N/A
- CVM N/A
- EPS Growth
- HYFM N/A
- CVM N/A
- EPS
- HYFM N/A
- CVM N/A
- Revenue
- HYFM $200,158,000.00
- CVM N/A
- Revenue This Year
- HYFM N/A
- CVM N/A
- Revenue Next Year
- HYFM $3.93
- CVM N/A
- P/E Ratio
- HYFM N/A
- CVM N/A
- Revenue Growth
- HYFM N/A
- CVM N/A
- 52 Week Low
- HYFM $0.43
- CVM $0.36
- 52 Week High
- HYFM $1.20
- CVM $3.08
- Technical
- Relative Strength Index (RSI)
- HYFM 48.16
- CVM 39.22
- Support Level
- HYFM $0.55
- CVM $0.37
- Resistance Level
- HYFM $0.60
- CVM $0.42
- Average True Range (ATR)
- HYFM 0.05
- CVM 0.03
- MACD
- HYFM -0.00
- CVM 0.00
- Stochastic Oscillator
- HYFM 31.40
- CVM 58.37
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.